<DOC>
	<DOCNO>NCT00605787</DOCNO>
	<brief_summary>The aim study evaluate short-term effect tetradecylthioacetic acid ( TTA ) plasma lipid glucose male patient type 2 diabetes mellitus dyslipidemia</brief_summary>
	<brief_title>TTA Treatment Diabetes Dyslipidemia</brief_title>
	<detailed_description>The tight linkage obesity , insulin resistance ( frank diabetes ) , dyslipidemia , hypertension widely observe name syndrome X , metabolic syndrome . For many year metformin drug clinical use effect insulin resistance . Recently , agonists peroxisome proliferator-activated receptor ( PPARs ) introduce treatment type 2 diabetes . The different PPARs seem activate wide range lipid lipid mediator , include fatty acid . 2-tetradecylthioacetic acid ( TTA ) modify fatty acid high affinity PPARgamma receptor . In animal model obesity-related insulin resistance ( obese Zucker rat dietary manipulate Wistar rat ) , TTA insulin sensitize effect enhance insulin mediate uptake glucose peripheral tissue . TTA treatment promote fatty acid catabolism experimental animal could casually link improve glucose tolerance . The protocol present study describe safety assessment therapeutic exploratory evaluation TTA small subset male type 2 diabetes patient 4 week . The primary safety parameter include general physical observational parameter , liver function test hematological parameter . To goal ass efficacy TTA select metabolic parameter include fast blood glucose insulin , fast plasma lipid , antioxidant status , fibrinolytic parameter , weight , BMI blood pressure .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>1- ( carboxymethylthio ) tetradecane</mesh_term>
	<criteria>type 2 diabetes mellitus HbA1c 8.012.0 % , fast Striacylglycerol 2.010.0 mmol/L , body mass index 2540 kg/m2 and/or waist/hip ratio &gt; 0.90. fast total cholesterol &gt; 10 mmol/L , blood pressure 170/110 mmHg significant disease Use corticosteroid , anticoagulant lipidlowering drug 2 week prior inclusion .</criteria>
	<gender>Male</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>